Long-term outcomes of patients with acromegaly: a report from the Swedish Pituitary Register

肢端肥大症 医学 垂体瘤 内科学 入射(几何) 放射治疗 儿科 激素 生长激素 内分泌学 光学 物理
作者
Steinunn Arnardóttir,Jacob Järås,Pia Burman,Katarina Berinder,Per Dahlqvist,Eva Marie Erfurth,Charlotte Höybye,Karin Larsson,Oskar Ragnarsson,Bertil Ekman,Britt Edén Engström
出处
期刊:European journal of endocrinology [Oxford University Press]
卷期号:186 (3): 329-339 被引量:12
标识
DOI:10.1530/eje-21-0729
摘要

To describe the treatment and long-term outcomes of patients with acromegaly from all healthcare regions in Sweden.Analysis of prospectively reported data from the Swedish Pituitary Register of 698 patients (51% females) with acromegaly diagnosed from 1991 to 2011. The latest clinical follow-up date was December 2012, while mortality data were collected for 28.5 years until June 2019.The annual incidence was 3.7/million; 71% of patients had a macroadenoma, 18% had visual field defects, and 25% had at least one pituitary hormone deficiency. Eighty-two percent had pituitary surgery, 10% radiotherapy, and 39% medical treatment. At the 5- and 10-year follow-ups, insulin-like growth factor 1 levels were within the reference range in 69 and 78% of patients, respectively. In linear regression, the proportion of patients with biochemical control including adjuvant therapy at 10 years follow-up increased over time by 1.23% per year. The standardized mortality ratio (SMR) (95% CI) for all patients was 1.29 (1.11-1.49). For patients with biochemical control at the latest follow-up, SMR was not increased, neither among patients diagnosed between 1991 and 2000, SMR: 1.06 (0.85-1.33) nor between 2001 and2011, SMR: 0.87 (0.61-1.24). In contrast, non-controlled patients at the latest follow-up from both decades had elevated SMR, 1.90 (1.33-2.72) and 1.98 (1.24-3.14), respectively.The proportion of patients with biochemical control increased over time. Patients with biochemically controlled acromegaly have normal life expectancy, while non-controlled patients still have increased mortality. The high rate of macroadenomas and unchanged age at diagnosis illustrates the need for improvements in the management of patients with acromegaly.
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
更新
PDF的下载单位、IP信息已删除 (2025-6-4)

科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
渡劫完成签到,获得积分10
刚刚
NexusExplorer应助科研通管家采纳,获得10
1秒前
ceeray23应助科研通管家采纳,获得10
1秒前
共享精神应助科研通管家采纳,获得10
1秒前
2秒前
jeff完成签到,获得积分10
3秒前
merrylake完成签到 ,获得积分10
4秒前
Kong完成签到,获得积分10
5秒前
eric888应助小趴菜采纳,获得200
5秒前
6秒前
ZHANGXUEJUN完成签到,获得积分10
6秒前
蔡从安发布了新的文献求助10
6秒前
burn完成签到,获得积分10
6秒前
muzi完成签到,获得积分10
7秒前
chao完成签到,获得积分10
8秒前
day_on发布了新的文献求助10
9秒前
一一完成签到,获得积分10
10秒前
orixero应助Champ采纳,获得10
10秒前
一点完成签到 ,获得积分0
10秒前
ZYN完成签到 ,获得积分10
12秒前
搜集达人应助永远的阿科采纳,获得20
13秒前
SYLH应助蔡从安采纳,获得10
13秒前
15秒前
照镜子丫dorime完成签到,获得积分10
17秒前
奉雨眠完成签到,获得积分10
17秒前
埋头苦干科研完成签到,获得积分10
18秒前
闫栋完成签到 ,获得积分10
18秒前
稳重的秋天完成签到,获得积分20
20秒前
20秒前
坐雨赏花完成签到 ,获得积分10
20秒前
文献狗完成签到,获得积分10
20秒前
DMMM完成签到,获得积分10
21秒前
day_on完成签到,获得积分10
21秒前
车非笑完成签到,获得积分10
21秒前
22秒前
玛卡巴卡发布了新的文献求助10
22秒前
王二哈完成签到,获得积分10
23秒前
芝麻福福完成签到,获得积分10
23秒前
曼夭非夭完成签到,获得积分10
24秒前
wang完成签到,获得积分10
25秒前
高分求助中
The Mother of All Tableaux Order, Equivalence, and Geometry in the Large-scale Structure of Optimality Theory 2400
Ophthalmic Equipment Market by Devices(surgical: vitreorentinal,IOLs,OVDs,contact lens,RGP lens,backflush,diagnostic&monitoring:OCT,actorefractor,keratometer,tonometer,ophthalmoscpe,OVD), End User,Buying Criteria-Global Forecast to2029 2000
Optimal Transport: A Comprehensive Introduction to Modeling, Analysis, Simulation, Applications 800
Official Methods of Analysis of AOAC INTERNATIONAL 600
ACSM’s Guidelines for Exercise Testing and Prescription, 12th edition 588
Residual Stress Measurement by X-Ray Diffraction, 2003 Edition HS-784/2003 588
T/CIET 1202-2025 可吸收再生氧化纤维素止血材料 500
热门求助领域 (近24小时)
化学 材料科学 医学 生物 工程类 有机化学 生物化学 物理 内科学 纳米技术 计算机科学 化学工程 复合材料 遗传学 基因 物理化学 催化作用 冶金 细胞生物学 免疫学
热门帖子
关注 科研通微信公众号,转发送积分 3950021
求助须知:如何正确求助?哪些是违规求助? 3495348
关于积分的说明 11076451
捐赠科研通 3225877
什么是DOI,文献DOI怎么找? 1783346
邀请新用户注册赠送积分活动 867596
科研通“疑难数据库(出版商)”最低求助积分说明 800839